|
Recent Molecular Events Concerned With Pathogenesis and Management of Diabetic Cardiomyopathy
|
|
| Author:
|
ARVIND JADON, ARVIND S. JADON, PUSHPENDRA KANNOJIA, VIVEK TOMAR
|
| Abstract:
|
Diabetic cardiomyopathy (DCM) is defined as the cardiovascular damage present in diabetic patients, which is characterized by myocardial dilatation and hypertrophy, as well as a decrease in systolic and diastolic function of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Diabetic cardiomyopathy (DCM) may be subclinical for a long time, before the appearance of clinical symptoms or signs. Its pathological substrate is characterized by the presence of myocardial damage, reactive hypertrophy, and intermediary fibrosis, structural and functional changes of the small coronary vessels, disturbance of the management of the metabolic cardiovascular load, and cardiac autonomic neuropathy. The disease is often associated with inadequate heart pumping and other heart function abnormalities. Cardiomyopathy is not common (affecting about 50,000 persons in the United States) but it can be severely disabling or fatal. Severe cases may result in heart failure and will require a heart transplant for patient survival. Classical and newer echocardiographic methods are available for early diagnosis. Currently, there is no specific treatment for DCM; targeting its pathophysiological substrate by effective risk management protects the myocardium from further damage and has a recognized primary role in its prevention.
|
| Keyword:
|
Diabetic Cardiomyopathy, Myocardial damage, Cardiac autonomic neuropathy, Ischemic heart disease, Hypertrophy
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|